Wipfli Financial Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Wipfli Financial Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7K	Buy	+693	New	+$7.86K	﹤0.01%	1966

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wipfli Financial Advisors's IRWD Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ironwood Pharmaceuticals (IRWD) in Q3 2022: 693 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1966 among its holdings.

245 funds tracked by Wall St. Rank hold IRWD as of Q3 2022.

Wipfli Financial Advisors held 693 shares of Ironwood Pharmaceuticals worth $7K as of Q3 2022.
Ironwood Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Ironwood Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1966 holding.
245 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.